Skip Navigation



JAC Advance Access published online on January 16, 2004
Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkh072
© 2004 by The British Society for Antimicrobial Chemotherapy
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
53/2/325    most recent
dkh072v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Saralaya, D.
Right arrow Articles by Etherington, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Saralaya, D.
Right arrow Articles by Etherington, C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2004 The British Society for Antimicrobial Chemotherapy

Original article

Serum and sputum concentrations following the oral administration of linezolid in adult patients with cystic fibrosis

Dinesh Saralaya 1 , Daniel G. Peckham 1 *, Bill Hulme 1 , Caroline M. Tobin 2 , Miles Denton 3 , Steve Conway 1 , and Christine Etherington 1

1 Regional Adult Cystic Fibrosis Unit, Seacroft Hospital, York Road, Leeds LS14 6UH;
2 Department of Microbiology, Southmead Hospital, Bristol BS10 5NB;
3 Department of Microbiology, Leeds Teaching Hospitals Trust, Leeds LS1 3EX, UK

* Corresponding author. E-mail: daniel.peckham{at}btinternet.com.

Received 11 July 2003 ; revised 23 October 2003 ; accepted 16 October 2003

Abstract

Objectives: Linezolid is a new oxazolidinone antibiotic with efficacy against a broad range of Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). In this study, we have determined the serum and sputum linezolid concentrations in adults with cystic fibrosis (CF) following oral drug administration.

Methods: Eleven adult patients with CF were recruited. Subjects received 600 mg of linezolid orally every 12 h for a total of six doses. Serum and sputum levels were measured just before and at 2 h after the final dose of linezolid. A further serum level was measured at 4 h.

Results: Ten adult patients completed the study. Mean (S.D.) serum linezolid concentrations were 2.3 mg/L (1.5) at 12 h following the fifth dose. At 2 and 4 h following the sixth dose, concentrations were 13.5 (4.3) and 8.1 (3.3). Mean (S.D.) linezolid sputum concentrations were 3.6 (2.1) and 17.4 (7.2) mg/L at 0 and 2 h following drug administration.

Conclusions: The oral administration of linezolid results in good sputum penetration in patients with CF. Mean levels exceed the required MIC for the treatment of MRSA for >80% of the dosing period for serum and the majority of the dosing period for sputum.

Keywords: oxazolidinones, MRSA, serum levels, pancreatic insufficient
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J Antimicrob ChemotherHome page
M. J. de Jesus Valle, N. S. Uranga, F. G. Lopez, A. D.-G. Hurle, and A. S. Navarro
Disposition of linezolid in the isolated rat lung after systemic and pulmonary drug delivery
J. Antimicrob. Chemother., November 1, 2007; 60(5): 1074 - 1079.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.